RALPH MCKENZIE: Open Payments
NPI 1932596897 · ROANOKE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$23,075 in 170 payments from 16 companies in 2025. Trend: 2023 $77,240 · 2024 $19,292 · 2025 $23,075
Speaker / faculty: $18,370Food & beverage: $2,628Travel & lodging: $2,077
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 34 | $15,476 |
| ABBVIE INC. | 46 | $6,087 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $266 |
| Neurocrine BioSciences, Inc. | 15 | $220 |
| Teva Pharmaceuticals USA, Inc. | 11 | $192 |
| Axsome Therapeutics, Inc. | 12 | $144 |
| Alkermes, Inc. | 6 | $140 |
| Otsuka America Pharmaceutical, Inc. | 6 | $130 |
| Janssen Pharmaceuticals, Inc | 4 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $87 |
Products named: FANAPT, VRAYLAR, CAPLYTA, INGREZZA, REXULTI, ARISTADA, UZEDY, AUSTEDO XR.
Industry payments across VA — which companies pay providers there.
